Nous-209: Off-the-Shelf Neoantigen Vaccine for Lynch Syndrome Cancer Prevention

Nous-209 is a cancer prevention vaccine developed by Italian biotech Nouscom in collaboration with MD Anderson and Memorial Sloan Kettering. Published in Nature Medicine in January 2026, the Phase 1b/2 trial enrolled 45 carriers of Lynch syndrome, a hereditary condition caused by inherited defects in DNA mismatch-repair genes that dramatically raises lifetime risk of colorectal and other cancers. The vaccine is unusual in being off-the-shelf rather than personalized. It packages approximately 200 frameshift neoantigens — mutated peptide sequences that recur across most mismatch repair deficient tumors because defective DNA repair tends to generate the same insertion-deletion errors. These shared neoantigens are delivered using a prime-boost strategy combining a gorilla adenoviral vector and a modified vaccinia Ankara (MVA) viral vector — the same vector platform repurposed from infectious-disease vaccine programs. Results were striking for an early-phase trial. All 37 evaluable participants developed neoantigen-specific T-cell responses, with a mean peak of roughly 1,100 IFN-gamma spot-forming cells per million peripheral blood mononuclear cells. Responses remained durable at one year in 85% of participants. No serious adverse events were reported. At one-year follow-up, researchers observed fewer precancerous lesions and no new advanced polyps among vaccinated carriers. The approach matters because Lynch syndrome carriers currently rely on aggressive colonoscopy surveillance and sometimes prophylactic surgery. A working immunoprophylactic vaccine could reshape how high-risk hereditary cancer is managed and serves as a proof of concept for shared-neoantigen approaches in other tumor mutational burden-high cancers.